Chicagoest thanks for posting that article. I think it shows investors the kind of effort that must go into pricing biotechs and also gives some insight as to how mispriced RVX is. Further I think it illustrates why before purchasing a stock a great many investors want to see the opinions of credible, independent analysts who go through these exercises as well as examine the science.  Could be wrong but I think RVX with all its baggage and history of disappointing investors definitely needs coverage from these types of analysts before the masses start charging in. Continued very positive CoVid news might help mitigate the company's credibility problem but good quality analyst coverage would also help enormously.